Abstract
Huatuo reconstruction pill (HTRP) is a traditional Chinese medicine prescription that mainly treats for hemiplegia and postoperation of brain stroke. Existing pharmacological studies have previously shown that HTRP could inhibit in vitro thrombosis, delay platelet adhesion, dilate blood vessels, and improve the microcirculation disturbances. In this paper, we chiefly concerned about the potential targets of HTRP and tried to figure out the active components of it. Computer-aided drug design method was emploied to search for the active components and explain the mechanism between the targets and the small molecules at molecular lever. The potential targets of this compound pharmaceutics were searched through relevant pharmacological studies and three pharmacophore models which involved the platelet activating factor (PAF) receptor, the angiotensin converting enzyme (ACE) and the 5-hydroxytryptamine receptor (5-HT2A) were constructed by Discotech method of Sybyl. Thus, the candidate compounds which agreed with the pharmacophore models were obtained by the virtual screening to the known ingredients of HTRP. Based on that, sequence and structure prediction of the unknown targets were realized by homology modeling which were used for molecular docking with those candidate compounds. Results showed that three compounds, which may prove to be valid to these targets, got higher scores than the existing corresponding inhibitors after molecular docking, including ferulic acid, onjixanthone I and albiflorin. And the three molecules may refer to the singificant substances to the total compounds of HTRP which were effective to the disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wang, B., Wu, X.Y., Yu, S.Q., Xiang, J.L. 2001. Progress in pharmacological and clinical studies on HUATUO ZAIZAO PILL. Chinese Traditional and Herbal Drugs (in Chinese) 32, 762–763.
Stafforini, D.M., Mclntyre, T.M., Zimmerman, G.A., Prescott, S.M. 2003. Platelet-activating factor, a pleiotropic mediator of physiological and pathological process. Critical reviews in clinical laboratory science 40, 643–672.
Masuyer, G., Schwager, S.L., Sturrock, E.D., Isaac, R.E., Acharya, K.R. 2012. Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Scientific Reports 2, 717–817.
Tanaka, N., Nakamura, E., Ohkura, M., Kuwabara, M., Yamashita, A., Onitsuka, T., Asada, Y., Hisa, H., Yamamoto, R. 2008. Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery. Clin Exp Pharmacol Physiol 35, 836–840.
Daniel, H., Jason, P.H., Graeme, R.M. 2002. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacological, Biochemistry and Behavior 71, 533–554.
Riccio, M., Pangrazi, P.P., Campodonico, A., Scalise, A., Marchesini, A., Talevi, D., Carboni, A., Bertani, C., Bertani, A., Mazzanti, L. 2007. Combined use of WEB2170 and HBO therapy can reduce ischemia and reperfusion injury to the skeletal muscle in a rabbit model. Micorsurgery 27, 43–47.
Guo, Y.S., Guo, Z.R. 2009. Comparative pharmacophore analysis of dual dopamine D2/5-HT2A receptor antagonists. Acta Pharmaceutica Sinica(in Chinese) 44, 314–320.
Patel, Y., Giliet, V.G., Bravi, G., Leach, A.R. 2002. A comparison of the pharmacophore identification programs: Catalsyst, DISCO and GASP. Journal of Computer-Aided Molecular Design 16, 653–681.
Langer, T., Wolber, G. 2004. Pharmacophore definition and 3D searches. Drug Discovery Today: Technologies 1, 203–207.
Joe, D., Zheng, O.Y., Jeffery, T., Andrew, B., Yaron, T., Jie, L. 2006. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Research 34, 116–118. doi: 10.1093/nar/gkl282.
Yeagle, P.L., Chio, G., Albert, A.D. 2001. Studies on the structure of the G-protein-coupled receptor rhodopsin including the putative G-protein binding site in unactivated and activated forms. Biochemistry 40, 11932–11937.
Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Soren, G..F., Thian, F.S., Kobika, T.S., Chol, H.J., William, I.W., Kobika, B.K., Stevens, R.C. 2007. High-resolution crystal structure of an engineered human β 2-adrenergic G protein-coupled receptor. Science 318, 1258–1265.
Sid, T., Michael, S. 2009. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem. Pharmacol 78, 11–20.
Goddard, W.A., Abrol, R. J. 2007. 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists. American Society for Nutrition 137, 15285–15385.
Natesh, R., Schwager, S.L., Sturrock, E.D., Acharya, K.R. 2003. Crystal structure of the human angiotensinconverting enzyme-lisinopril complex. Nature 421, 551–554.
Fu, W., Liu, H.F., Li, B. (2011) A pharmacophore model and database searching for serotonin 2A receptor antagonists. Sciencepaper Online. http://www.paper.edu.cn/enreleasepaper/content/4404495.
Nie, J., Dong, X.C., Pan, J.H. 2003. Comparison of modified CoMFAs in study of PAF antagonist. Acta Chimica Sinica (in Chinese) 61, 1129–1135.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, KZ., Jiang, YG., Zuo, Y. et al. Establishment of the method for screening the potential targets and effective components of huatuo reconstruction pill. Interdiscip Sci Comput Life Sci 6, 125–132 (2014). https://doi.org/10.1007/s12539-013-0056-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12539-013-0056-1